tiprankstipranks
Trending News
More News >
IPCA Laboratories Limited (IN:IPCALAB)
:IPCALAB
India Market
Advertisement

IPCA Laboratories Limited (IPCALAB) Price & Analysis

Compare
0 Followers

IPCALAB Stock Chart & Stats


Financials

IPCALAB FAQ

What was IPCA Laboratories Limited’s price range in the past 12 months?
IPCA Laboratories Limited lowest stock price was ₹1181.80 and its highest was ₹1757.65 in the past 12 months.
    What is IPCA Laboratories Limited’s market cap?
    IPCA Laboratories Limited’s market cap is ₹370.83B.
      When is IPCA Laboratories Limited’s upcoming earnings report date?
      IPCA Laboratories Limited’s upcoming earnings report date is Aug 19, 2025 which is in 31 days.
        How were IPCA Laboratories Limited’s earnings last quarter?
        IPCA Laboratories Limited released its earnings results on May 29, 2025. The company reported ₹8.74 earnings per share for the quarter, missing the consensus estimate of ₹8.767 by -₹0.027.
          Is IPCA Laboratories Limited overvalued?
          According to Wall Street analysts IPCA Laboratories Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
            Does IPCA Laboratories Limited pay dividends?
            IPCA Laboratories Limited pays a Semiannually dividend of ₹4 which represents an annual dividend yield of 0.55%. See more information on IPCA Laboratories Limited dividends here
              What is IPCA Laboratories Limited’s EPS estimate?
              IPCA Laboratories Limited’s EPS estimate is 9.07.
                How many shares outstanding does IPCA Laboratories Limited have?
                IPCA Laboratories Limited has 253,704,220 shares outstanding.
                  What happened to IPCA Laboratories Limited’s price movement after its last earnings report?
                  IPCA Laboratories Limited reported an EPS of ₹8.74 in its last earnings report, missing expectations of ₹8.767. Following the earnings report the stock price went down -1.798%.
                    Which hedge fund is a major shareholder of IPCA Laboratories Limited?
                    Currently, no hedge funds are holding shares in IN:IPCALAB

                    Company Description

                    IPCA Laboratories Limited

                    IPCA Laboratories Limited (IPCALAB) is a leading Indian pharmaceutical company engaged in the manufacturing and marketing of pharmaceutical formulations, active pharmaceutical ingredients (APIs), and intermediates. With a robust product portfolio, IPCA caters to various therapeutic segments including cardiovascular, anti-diabetic, anti-malarial, and anti-inflammatory medications. The company's operations span across domestic and international markets, with a strong presence in over 120 countries.

                    IPCALAB Stock 12 Month Forecast

                    Average Price Target

                    ₹1,435.00
                    ▼(-4.06%Downside)
                    {"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1130":"₹1,130","1697":"₹1,697","1271.75":"₹1,271.8","1413.5":"₹1,413.5","1555.25":"₹1,555.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":1520,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">₹1.52K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1435,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">₹1.44K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1350,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">₹1.35K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1130,1271.75,1413.5,1555.25,1697],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Dec<br/>2024","9":"Feb<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1372,1383.3846153846155,1394.7692307692307,1406.1538461538462,1417.5384615384614,1428.923076923077,1440.3076923076924,1451.6923076923076,1463.076923076923,1474.4615384615386,1485.8461538461538,1497.2307692307693,1508.6153846153845,{"y":1520,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1372,1376.8461538461538,1381.6923076923076,1386.5384615384614,1391.3846153846155,1396.2307692307693,1401.076923076923,1405.923076923077,1410.7692307692307,1415.6153846153845,1420.4615384615386,1425.3076923076924,1430.1538461538462,{"y":1435,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1372,1370.3076923076924,1368.6153846153845,1366.923076923077,1365.2307692307693,1363.5384615384614,1361.8461538461538,1360.1538461538462,1358.4615384615386,1356.7692307692307,1355.076923076923,1353.3846153846155,1351.6923076923076,{"y":1350,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1148.84,"date":1717200000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1131.29,"date":1719792000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1301.1,"date":1722470400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1377.94,"date":1725148800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1488.64,"date":1727740800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1585.77,"date":1730419200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1532.7,"date":1733011200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1696.85,"date":1735689600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1443,"date":1738368000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1443,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1353.45,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1423.25,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1372,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
                    Similar Stocks
                    Company
                    Price & Change
                    Follow
                    Ajanta Pharma Limited
                    Biocon Limited
                    Gland Pharma Ltd.
                    Glenmark Pharmaceuticals Limited
                    Laurus Labs Ltd.
                    Popular Stocks
                    What am I Missing?
                    Make informed decisions based on Top Analysts' activity
                    Know what industry insiders are buying
                    Get actionable alerts from top Wall Street Analysts
                    Find out before anyone else which stock is going to shoot up
                    Get powerful stock screeners & detailed portfolio analysis